Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2010

View Archived Issues

Novel extended-release, tamper-resistant formulation of oxycodone shows favorable PK

Merck KGaA identifiies novel oral heat shock protein 90 inhibitors for cancer

Novartis claims novel farnesyl pyrophosphate synthase inhibitors

Boehringer Ingelheim discloses novel 11beta-HSD1 inhibitors

UCB presents novel PI3K inhibitors

Novel KCNQ2/3 channel modulators claimed by Gruenenthal scientists

GlaxoSmithKline describes novel antibacterial agents

FDA requires more data before approving naproxcinod NDA for osteoarthritis

Viralytics set to meet with FDA to review proposed phase II melanoma study

Nymox reports safety monitoring committee update for phase III NX-1207 trials

Capstone Therapeutics continues second phase II AZX-100 trial

Resverlogix completes dosing in phase II ASSERT trial ahead of schedule

Soligenix completes enrollment in phase II trial of orBec in acute GVHD prevention

NexMed presents preclinical results for Vitaros in wound healing

Omeros selects clinical candidate for MASP-2 antibody program

PLx Pharma receives multiple grants from the NIH for developing safer NSAIDs

VGX-100 enhances antitumor effects of bevacizumab/docetaxel in vivo

Preclinical data support safety and potent antitumor activity of C-BiTE antibody

TransVax CMV vaccine safe and immunogenic up to 1 year in HSCT patients

Idenix Pharmaceuticals reports interim phase II and other data on anti-HCV treatments

Boston Scientific obtains E.U. approval for Taxus Element Stent System

Rabeprazole treatment beneficial in patients with functional dyspepsia

FDA approves IND application for AEZS-108 in bladder cancer

Pfizer to acquire Ergonex Pharma's investigational treatment for PAH

RegeneRx receives NIH grant for development of its heart attack drug RGN-352

GSK and Dong-A enter strategic alliance to copromote their products in South Korea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...